

Bangladesh

Support for Vaccine: Pneumococcal This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Bangladesh																								
2. Vaccine grant number:	13-BGD-08a-Y, 1316-BGD-12b-X, 1316-BGD-12b-Y, 1718-BGD-12b-X, 18-BGD-12a-X, 18-BGD-25a-Y, 1921-BGD-12a-X, 2022-BGD-12a-X																								
3. Date of Decision Letter:	30/09/2019																								
4. Date of the Partnership Framework Agreement:	24 June 2013																								
5. Programme title:	New Vaccine Support (NVS), Pneumococcal , Routine																								
6. Vaccine type:	Pneumococcal																								
7. Requested product presentation and formulation of vaccine:	PCV10, 4 dose(s) per vial, LIQUID																								
8. Programme Duration: ¹	2013-2022																								
9. Programme Budget (indicative): ²	(subject to the terms of the Partnership Framework Agreement)																								
	2013-2019	2020	2021	2022	2023	2024	Total ²																		
Programme Budget (US\$)	202,852,741	35,848,500	31,336,500	25,235,500	-	-	295,273,241																		
10. Vaccine introduction grant	<table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th colspan="3">Approval</th> </tr> <tr> <th>Year</th> <th>Grant Number</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>2013</td> <td>13-BGD-08a-Y</td> <td>3,233,500</td> </tr> </tbody> </table> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th colspan="2">Disbursement</th> </tr> <tr> <th>Disbursement date</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>14 July, 2014</td> <td>3,233,500</td> </tr> </tbody> </table>							Approval			Year	Grant Number	Amount (US\$)	2013	13-BGD-08a-Y	3,233,500	Disbursement		Disbursement date	Amount (US\$)	14 July, 2014	3,233,500			
Approval																									
Year	Grant Number	Amount (US\$)																							
2013	13-BGD-08a-Y	3,233,500																							
Disbursement																									
Disbursement date	Amount (US\$)																								
14 July, 2014	3,233,500																								
11. Product switch grant	<table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th colspan="3">Approval</th> </tr> <tr> <th colspan="3"><i>Approval</i></th> </tr> <tr> <th>Year</th> <th>Grant Number</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>2018</td> <td>18-BGD-25a-Y</td> <td>279,715</td> </tr> </tbody> </table> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th colspan="2">Disbursement</th> </tr> <tr> <th>Disbursement date</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>15 August, 2018</td> <td>279,715</td> </tr> </tbody> </table>							Approval			<i>Approval</i>			Year	Grant Number	Amount (US\$)	2018	18-BGD-25a-Y	279,715	Disbursement		Disbursement date	Amount (US\$)	15 August, 2018	279,715
Approval																									
<i>Approval</i>																									
Year	Grant Number	Amount (US\$)																							
2018	18-BGD-25a-Y	279,715																							
Disbursement																									
Disbursement date	Amount (US\$)																								
15 August, 2018	279,715																								
12. Indicative Annual Amounts: ³	(subject to the terms of the Partnership Framework Agreement)																								

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Type of supplies to be purchased with Gavi funds	2014-2019	2020	2021
Number of vaccine doses		10,757,500	-
Annual Amounts (US\$)	202,852,741	35,848,500	-

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement: Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group: Preparatory transition phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	1,274,000	1,409,600	3,392,000	-	-
Number of AD syringes	1,262,400	1,396,800	3,361,200	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	13,900	15,375	36,975	-	-
Value of vaccine doses (US\$)	3,885,061	4,298,734	10,344,582	-	-
Total co-financing payments (US\$) (including freight)	3,974,500	4,401,500	10,591,500	-	-

16. Operational support for campaigns:
Not applicable

17. Additional Reporting Requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:	
<ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; 	31 March 2020
<ul style="list-style-type: none"> number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. 	15 May 2020

<ul style="list-style-type: none"> Countries shall report the actual switch date in the first renewal request following the actual implementation. 	N/A
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
<p>18. Financial clarifications: Country shall provide the following clarifications to Gavi*:</p> <p>Not applicable</p> <p>* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.</p>	
<p>19. Other conditions:</p> <p>Not applicable</p>	

Signed by,

On behalf of Gavi



Thabani Maphosa

Managing Director, Country Programmes a.i.

30/09/2019